Home Cart Sign in  
Chemical Structure| 1898207-64-1 Chemical Structure| 1898207-64-1

Structure of DS-1001b
CAS No.: 1898207-64-1

Chemical Structure| 1898207-64-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DS-1001b is a novel selective mutant IDH1 inhibitor with antitumor activity.

Synonyms: DS-1001

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DS-1001b

CAS No. :1898207-64-1
Formula : C29H29Cl3FN3O4
M.W : 608.92
SMILES Code : CC(N)(C)C.O=C(O)/C=C/C1=CC=CC2=C1C(C)=CN2C(C3=C(C(C)(F)C)ON=C3C4=C(Cl)C=C(Cl)C=C4Cl)=O
Synonyms :
DS-1001
MDL No. :MFCD32263044
InChI Key :UPPAAWQBZQBNIE-USRGLUTNSA-N
Pubchem ID :139600317

Safety of DS-1001b

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
LN18 cells 5 µM 24 h To evaluate the inhibitory effect of DS-1001b on IDH1 R132C/S280F and R132H/S280F variants, results showed that DS-1001b effectively reduced 2-HG levels. PMC9378673

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04458272 WHO Grade II Glioma PHASE2 ACTIVE_NOT_RECRUITING 2026-06-30 Nagoya University Hospital, Na... More >>goya, Aichi, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kyoto University Hospital, Kyoto, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Kyorin University Hospital, Tokyo, Japan|National Cancer Center Hospital, Tokyo, Japan|Tokyo Women's Medical University Hospital, Tokyo, Japan Less <<
NCT03030066 Glioma ACTIVE_NOT_RECRUITING 2026-03-01 National Cancer Center Hospita... More >>l, Tokyo, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.64mL

0.33mL

0.16mL

8.21mL

1.64mL

0.82mL

16.42mL

3.28mL

1.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories